3 results
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…
Primary:To evaluate the efficacy and safety of Ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor (TKI).Secondary:To obtain additional…
Primary:To evaluate the effects of pirepemat on falls frequency as compared to placebo.Secundary:To evaluate the effects of pirepemat on Parkinson's disease motor symptoms as compared to placebo.To evaluate the effects of pirepemat on apathy as…